VialKLOW 80 mg pre-filled pen
TB-500 + BPC-157 + GHK-Cu + KPV
Four-peptide repair blend
Four repair and renewal compounds in one pen.
- Ships from Canada in 1–2 business days
- Free shipping over $120
Place your order, then send the e-Transfer. We pack it as soon as it arrives.
For research use only. Not for human consumption.
Complete your setup
Pre-filled, with 4 pen needles in the box. Just add wipes.
- Alcohol Wipes
Free · To wipe the pen's rubber seal
Compare. Side by side, from the research.
About KLOW
KLOW combines four compounds studied across repair and renewal: TB-500, BPC-157, GHK-Cu, and KPV. The inclusion of GHK-Cu gives it a foot in both the Foundation and Longevity families.
How it works
- Layered Mechanisms
- Four compounds studied for distinct but adjacent pathways across tissue repair, remodeling, and inflammatory tone.
- Crossover Profile
- The GHK-Cu component is studied for skin and connective-tissue renewal, which is why this sits across two families.
What you need
- Alcohol Wipes
- A protocol guide comes with every order
Shipping & payment
- Packed and dispatched within 1–2 business days
- Delivered across Canada in 2–5 business days, tracked
- Temperature-controlled packaging where the product needs it
- Free shipping on orders over $120
- Prices in CAD · pay by Interac e-Transfer
- Format
- Disposable pre-filled pen · 4 pen needles included
- Strength
- 80 mg per pre-filled pen
- Storage
- Refrigerate, away from light.
- Route in research
- Subcutaneous
- SKU
- KLOW80DSP
- Purity
- High-performance liquid chromatography (HPLC), by an independent laboratory
- Identity
- Mass spectrometry, on the same batch
- How often
- Every batch
- COA
- The certificate of analysis is matched to the lot code printed on your vial
- Evidence
- Preclinical
Check your lot
Every vial carries a lot code. Enter it, or scan the QR on the label, to see its expiry and certificate of analysis.
PreclinicalThe four-compound KLOW blend has not been evaluated as a combination, and research on its components comes mainly from animal and cell studies, with only small, limited human reports for BPC-157.
What research examines
- Musculoskeletal soft tissue healing in animal models (BPC-157)
- Wound healing and epithelial repair (BPC-157)
- Skin and connective-tissue renewal (GHK-Cu)
- Gene expression linked to regenerative and protective actions (GHK-Cu)
- Cytoskeletal regulation in tissue repair (TB-500)
- Inflammatory balance (KPV)
Reported in studies
- Human safety data for the combined blend are limited
- Adverse events for the four-compound combination have not been characterized in published studies
- Recent narrative review literature has raised open questions about the risk-benefit profile of BPC-157
- Human evidence for BPC-157 is limited to small reports, so safety conclusions remain preliminary
Published research protocols
4 mg, daily, am fasted
Research protocols have used 2–4 mg per administration, once daily (morning, fasted), in 8-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
CoreX AI
Ask about KLOW
Plain answers, from the basics to the studies.
Research information, not medical advice.
Often researched with KLOW
Vial
Vial
FAQ
Questions, answered
KLOW is a research blend that combines four compounds in one vial: TB-500, BPC-157, GHK-Cu, and KPV. Each component has been studied in its own right across tissue repair, remodeling, and inflammatory signaling. Because GHK-Cu is also studied for skin and connective-tissue renewal, the blend is grouped in both the Foundation and Longevity families. The combination itself has not been studied as a single formulation in published research.
Each compound is studied for a different step in repair. TB-500 is associated with cytoskeletal regulation, BPC-157 with angiogenic and epithelial signaling, GHK-Cu with copper-dependent tissue remodeling, and KPV with inflammatory balance. The rationale for the blend is that these distinct but adjacent pathways may be relevant to tissue repair together. Whether combining them produces additive or different effects has not been established experimentally.
BPC-157 has been reviewed for musculoskeletal soft tissue healing, wound healing, and emerging orthopaedic sports medicine applications, largely based on animal work. GHK-Cu has been studied for regenerative and protective actions, including gene expression data, anti-aging research, and topical anti-wrinkle applications. TB-500 and KPV are studied for cytoskeletal regulation and inflammatory balance, respectively. Published research on the four-compound blend as a combination is not available.
Human safety data for the KLOW blend are limited, and adverse events for the combined formulation have not been characterized in published studies. Evidence for BPC-157 in humans consists of small reports, and recent narrative review literature has questioned whether its regenerative potential is balanced by adequately understood risks. Safety conclusions for each component, and especially for their combination, should be regarded as preliminary.
Research protocols have used 2–4 mg per administration, once daily in the morning in a fasted state, in 8-week blocks followed by 4 weeks off, delivered by the subcutaneous route. These figures describe what protocols have used rather than an established or validated dose, as the blend has not been evaluated in controlled studies. Each CoreX order ships with a protocol guide for laboratory reference.
You may also like
Vial · Pen
Vial
Vial
Vial